SAN DIEGO, Oct. 27 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN)
will host a conference call on Wednesday, November 2, 2005 at 4:30 p.m.
Eastern (1:30 p.m. Pacific) to discuss 2005 third quarter financial results.
The financial results press release will be issued at close of market on
Audio of management's presentation will be available via live webcast on
the investor relations section of Nanogen's corporate website at
www.nanogen.com, and will be archived for 90 days. A digital recording of the
call will also be available for 48 hours, beginning two hours after the
completion of the conference call on November 2, and can be accessed via
telephone at (877) 660-6853 for US/Canada participants, and (201) 612-7415 for
international participants. The account number, 286, along with the
conference ID, 173540, will be required to listen to the playback.
About Nanogen, Inc.
Nanogen's advanced technologies provide researchers, clinicians and
physicians worldwide with improved methods and tools to predict, diagnose, and
ultimately help treat disease. The company's products include real-time PCR
reagents, the NanoChip(R) electronic microarray platform and a line of rapid
diagnostic tests. Nanogen's ten years of pioneering research involving
nanotechnology holds the promise of miniaturization and continues to be
supported for its potential for diagnostic and biowarfare applications. For
additional information please visit Nanogen's website at www.nanogen.com.
This press release contains forward-looking statements that are subject to
risks and uncertainties that could cause actual results to differ materially
from those set forth in the forward-looking statements, including whether
patents owned or licensed by Nanogen will be developed into products, whether
the patents owned by Nanogen offer any protection against competitors with
competing technologies, whether products under development can be successfully
developed and commercialized, whether results reported by our customers or
partners can be identically replicated, and other risks and uncertainties
discussed under the caption "Factors That May Affect Results" and elsewhere in
Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date hereof. Nanogen disclaims any intent or obligation to update these
SOURCE Nanogen, Inc.